Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New PET scan agent could spot bladder cancer earlier

NCT ID NCT04897763

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new imaging agent called 89Zr-girentuximab in 6 people with non-muscle-invasive bladder cancer. The goal was to see if it could safely and clearly show tumors on PET/CT scans. Researchers looked for uptake spots in the bladder and checked for side effects up to 30 days after injection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

6 people

The number who actually took part.

Started

Dec 2021

Finished

Sep 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening evaluations. * Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. * Female or male, Age ≥ 18 years at time of study entry. * Performance Status: 0 or 1. * Clinical evidence of NMIBC based on cystoscopy and proven histologically of papillary tumors. * Histologically-confirmed pTa Grade 3 or pT1 Grade 3 bladder cancer patients relapsing without muscle invasion. * Negative sterile Urine cytobacteriological testing at baseline (T0). * Consent to use a contraception method for at least 30 days after administration of 89Zr-girentuximab. * Patient has valid health insurance. Exclusion Criteria: * Patient with urinary incontinence. * Known hypersensitivity to girentuximab. * Exposure to any experimental diagnostic or therapeutic drug within 30 days prior the date of planned administration of 89Zr-girentuximab * Exposure to any radiopharmaceutical within 30 days (corresponding to 10 half-lives of Zr-89) prior to the administration of 89Zr-girentuximab * Patients suffering from a bladder cancer at stage pT2, pT3 or pT4 * Serious non-malignant disease that may interfere with the objectives of the study or with the safety or compliance of the patient; as judged by the investigator * Concomitant cancer in the past 5 years except cutaneous cancers (except melanoma) and in situ carcinoma * Prior chemotherapy, radiotherapy (other than short cycle of palliative radiotherapy), immunotherapy within 21 days of 89Zr-girentuximab administration * Patients with known human immunodeficiency viruses (HIV), Hepatitis B virus (HBV) and Hepatitis C Virus (HCV) infections, * Pregnant or likely to be pregnant or nursing patient. * Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study * Persons deprived of their liberty, under a measure of safeguard of justice, under guardianship or placed under the authority of a guardian.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bladder cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Institut de cancerologie de l'Ouest

    Saint-Herblain, 44805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.